Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapulmonary Penetration of Nacubactam in Healthy Volunteers
NCT03182504Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2017
- Primary completion
- Aug 2017
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nacubactam in gram-negative bacterial infections, sponsored by Roche. Primary endpoint: Epithelial Lining Fluid (ELF) Concentration of Nacubactam to Plasma Concentration of Nacubactam Ratio at 8 hours. Started Jun 2017; status: completed.
02
Drugs
Nacubactam
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT03182504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182504.